AUTL
Autolus Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$369.94M
P/E Ratio
—
EPS
$-1.08
Beta
2.00
52W High
$2.70
52W Low
$1.10
50-Day MA
$1.48
200-Day MA
$1.69
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | $1.08M |
| Gross Profit (TTM) | $-26.48M |
| EBITDA | $-68.94M |
| Operating Margin | -6571.00% |
| Return on Equity | -29.60% |
| Return on Assets | -22.30% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.67 |
| Price-to-Book | 2.11 |
| Price-to-Sales (TTM) | 343.01 |
| EV/Revenue | 1.936 |
| EV/EBITDA | 0.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83655.00% |
| Shares Outstanding | $266.14M |
| Float | $33.90M |
| % Insiders | 5.56% |
| % Institutions | 78.99% |
Analyst Ratings
Consensus ($8.79 target)
1
Strong Buy10
BuyData last updated: 4/7/2026